We turn the page to the start of a new year that emphasizes the importance of integration with our customers, ensuring the instabilities of the market (post Covid19) are overcome with reliability and efficiency.
At EarlyHealth Group, we continue down the path of a globalized entity as to ensure flexibility, stability and efficiency in the services we offer across our global footprint.
This year we continue our investment and growth in CTM services, offering not only kit production, labelling, packaging and QP release from our European site, but growing the same benchmarked services to our new sites in California, USA and Chennai, India. We strongly believe supporting our customers with these services, combined with material and comparator sourcing, is fundamental to ensuring clinical study stability and budget.
Our Managed Access Program has seen many achievements in 2021, and we target this year to manage the exclusive rights of over +50 medicines that are vital to patients.
We have been honored to have had the opportunity to keep building a team of specialized individuals, whose synergy together has had a clear impact on the success of our customers. Our culturally diverse team has been growing rapidly and we aim to reach over 100 key team members by the end of the year.
Thanking all our stakeholders for this opportunity to make a positive impact in the life sciences industry, and being able year-on-year to grow on this path.